Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
tRNA (guanine(26)-N(2))-dimethyltransferase (TRMT1) is an enzyme responsible for catalyzing the formation of N2,N2-dimethylguanosine (m(^{2,2})G) at position 26 in both cytoplasmic and mitochondrial tRNAs[4][5]. This modification supports efficient protein translation and helps maintain redox homeostasis in cells, protecting them against oxidative stress[1][4]. TRMT1 contains a C-terminal zinc finger motif critical for its function, uses S-adenosyl methionine as a methyl donor, and its deficiency or mutation results in decreased tRNA methylation, lowered protein synthesis, higher oxidative stress, and is implicated in certain forms of autosomal recessive intellectual disorder[4][5]. The enzyme is a direct human substrate for SARS-CoV-2 main protease (Mpro), which can cleave and inactivate TRMT1, further highlighting its importance in cell biology and stress responses[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on tRNA (guanine(26)-N(2))-dimethyltransferase (TRMT1).